An approach to personalized cell therapy in chronic complete paraplegia: The Puerta de Hierro phase I/II clinical trial

Cytotherapy cover

Personalized cell therapy with MSCs is safe and leads to clear improvements in clinical aspects and quality of life for patients with complete and chronically established paraplegia.

Source: Summary of Website

Identification
Category
Document type
Research
ISBN/ISSN/NIPO
ISSN 1465-3249
Bibliographic data
Place of publication
London
Magazine
Cytotherapy
Volume
18
Issue
8
Retrieved
Year
2016
Month
August
Pages
1025-1036
Language
English
Additional Information
Source
AT Observatory